Board of Directors
Robert Thomas (Non Executive Chairman)
Seth Harrison M.D. (Deputy Chairman, Non Executive Director)
Douglas Godshall (Chief Executive Officer, Executive Director)
Dr Christine Bennett (Non-Executive Director)
Dr Denis Wade, AM (Non-Executive Director)
Mr Robert (Bob) Stockman, (Non Executive Director)
Mr Timothy J. Barberich, (Non Executive Director)
Management
Douglas Godshall (Chief Executive Officer, Executive Director)
Dozier Rowe (Chief Operating Officer)
David McIntyre (Chief Financial Officer, Company Secretary)
Jeffrey A. LaRose (Chief Scientific Officer)
Dr David R. Hathaway (Chief Medical Officer)
Howard Leibman (Head of Corporate Development)
James Schuermann (Vice President, Sales and Marketing)
Jennifer Foley (Vice President, Clinical and Regulatory Affairs)
Medical Advisory Board
Bud Frazier, M.D.
Steven Boyce, M.D.
Leslie Miller, M.D.
Laman A. Gray, Jr., M.D.
Stephen Westaby M.D., Ph.D
Georg Wieselthaler, M.D.
Gerrie O'Driscoll, M.D.
Board of Directors
 |
Robert Thomas Non Executive Chairman |
Rob Thomas has over 30 years experience in the securities industry, having recently retired as Chairman, Global Corporate & Investment Bank, Australia and New Zealand of Citigroup Global Markets Australia Pty Limited. In 1986 Rob joined County NatWest Securities Australia Limited to establish its stockbroking operations and was appointed Managing Director.
This ultimately involved the acquisition of a small 30 person Sydney operation, JM Bowyer & Co., which was built up to 220 staff with operations in Melbourne, London, New York, Auckland, and Tokyo with a consistent No.1 Market Share rating in Australia during the 1990's. In April 1998, County NatWest Securities was taken over by Salomon Smith Barney and Mr Thomas was ultimately appointed Chief Executive Officer of Australia and New Zealand.
Rob is also Chairman of the Securities & Derivatives Industry Association and Deputy Chairman of Benitec Limited. He holds a Bachelor of Economics from Monash University 1963-1966 and has been a member of the Securities Institute of Australia since 1976 and was appointed a fellow to the Institute in 1997.
 |
Seth Harrison M.D. Deputy Chairman, Non Executive Director |
Dr. Harrison has invested in life sciences since 1991. Currently he is the managing general partner of Apple Tree Partners, a life sciences venture capital firm. Prior to founding Apple Tree, Dr. Harrison was a general partner at Oak Investment Partners and earlier had been a venture partner at Sevin Rosen Funds. His exited investments include: ArQule, Coelacanth, Cyrano Sciences, Informed Access, Ultracision and ViroPharma.Current portfolio investments include Structural GenomiX and GeneOS Oy. Dr. Harrison serves as founding investor, acting CEO and chairman of numerous portfolio companies.
He received an AB from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital. Dr. Harrison serves on the board of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnerships engaged in the development of anti-HIV microbicides. He is also Chairman of the Board of Trustees of the New York Studio School for Drawing, Painting and Sculpture.
Douglas Godshall
Chief Executive Officer (effective from 18 September 2006), Executive Director (effective from 31 October 2006)
Douglas Godshall has been since January 2005 President, Vascular Surgery at Boston Scientific, with overall responsibility for a business division employing some 600 personnel and generating revenues of approximately US$100M. Mr Godshall previously spent five years as Vice President, Business Development at Boston Scientific, where he was instrumental in developing the acquisition strategies for the cardiology, electrophysiology, neuroradiology and vascular surgery divisions. During this period Mr Godshall led the negotiation and structuring of over 70 transactions and represented Boston Scientific on the Boards of 11 companies. Prior to assuming the Business Development position, he was Director of Marketing for Boston Scientific's Urology Division where he helped build global sales to over US$150M. Mr. Godshall joined Boston Scientific in 1990.
 |
Dr Christine Bennett Non-Executive Director |
Dr Bennett is an experienced company director, with a diverse background in clinical care, strategic planning, capital raising, advisory work and senior management in both the public and private health sectors.
Dr Bennett is Chief Executive Officer of Research Australia Limited, a national alliance of organizations promoting health and medical research. Dr Bennett has previously been a Health and Life Sciences Partner at KPMG Australia, Chief Executive Officer of Westmead Hospital (Sydney), Director of Clinical Services, South Eastern Sydney Area Health, Associate Director in the New South Wales Department of Health and a Paediatric Registrar at Prince of Wales Children's Hospital (Sydney).
Dr Bennett's other directorships include Resonance Health Limited. Dr Bennett holds a bachelor of medicine and surgery (University of Sydney), Master of Paediatrics (University of NSW) and is a Fellow of the Royal Australasian College of Physicians.
 |
Dr Denis Wade, AM Non-Executive Director |
Dr Wade has a depth of experience in the development of research based health care products in Australia and commercialisation of these technologies in the global market.
Dr Wade was formerly Managing Director of Johnson & Johnson Research Pty Ltd ("J&J") from 1988-2003 and Chairman from 1989 to March 2003.
For 10 years he was a member of J&J's US-based Corporate Office of Science & Technology and its Business Development Council. He was the former Foundation Professor of Clinical Pharmacology at the University of New South Wales. Dr Wade also serves on industry bodies in Australia, is a former President of the Australian Society of Clinical and Experimental Pharmacology and has held senior positions in the International Union of Pharmacology, serving as Chairman of the Clinical Pharmacology Section.
Dr Wade's other directorships include Cryptome Pharmaceuticals Limited. Dr Wade holds a bachelor of medicine and surgery, is a Fellow of the Royal Australasian College of Physicians and a Fellow of the Australian Academy of Technological Sciences and Engineering.
Robert (Bob) Stockman
Non-Executive Director (effective from 11 December 2006)
Robert (Bob) Stockman is the President and CEO of Group Outcome LLC, a US ba sed merchant banking firm which deploys its capital and that of its financial partners in private equity and venture capital investments in medical technology companies. He is also the Chairman of REVA Medical, Inc, a stent company which he helped co-found.
Bob has played a critical role in a number of buyout transactions in which Group Outcome LLC successfully led the recapitalization, turnaround and subsequent sale of various medical companies. These include Ioptex Research, a manufacturer of intraocular lenses, and two separate Johnson & Johnson divisions, Critikon and "A" Company Orthodontics.
Timothy J. Barberich
Non-Executive Director (effective from 30 April 2008)
Barberich is the founder and former president, chief executive officer and chairman of Marlborough, MA-based Sepracor Inc., a publicly traded pharmaceutical company with 2007 revenues of US$1.2 billion that specializes in developing drugs for respiratory and central nervous system disorders. Barberich founded Sepracor in 1984 and was president and chief executive officer through 1999 when he also became chairman. He retired in May 2007 but remains Sepracor's chairman.
Barberich also serves on the boards of BioSphere Medical, Gemin X Biotechnologies, Resolyx Pharmaceuticals and serves on the Board of Trustees of Boston Medical Center.
Prior to founding Sepracor, Barberich spent 10 years as a senior executive at Bedford, MA-based Millipore Corporation, a company that provides separations products to the life science research, pharmaceutical, biotechnology and electronic markets.
Barberich is a graduate of Kings College. He holds a BS degree in Chemistry.
Management
HeartWare's management team has a range and depth of relevant experience key to HeartWare's ability to fulfil its plans. The current organisational structure is set out below.
Douglas Godshall
Chief Executive Officer (effective from 18 September 2006), Executive Director (effective from 31 October 2006)
Douglas Godshall has been since January 2005 President, Vascular Surgery at Boston Scientific, with overall responsibility for a business division employing some 600 personnel and generating revenues of approximately US$100M. Mr Godshall previously spent five years as Vice President, Business Development at Boston Scientific, where he was instrumental in developing the acquisition strategies for the cardiology, electrophysiology, neuroradiology and vascular surgery divisions. During this period Mr Godshall led the negotiation and structuring of over 70 transactions and represented Boston Scientific on the Boards of 11 companies. Prior to assuming the Business Development position, he was Director of Marketing for Boston Scientific's Urology Division where he helped build global sales to over US$150M. Mr. Godshall joined Boston Scientific in 1990.
Dozier Rowe
Chief Operating Officer
Dozier Rowe brings to HeartWare over 25 years of experience in the medical device industry, having held senior positions at Boston Scientific Corporation, St Jude Medical Inc. and Baxter Healthcare Corporation. He has worked with a variety of Class III implantable medical devices, with responsibility across all elements of manufacturing, quality control, regulatory affairs, materials management, supply chain and operations. Prior to establishing his own manufacturing consulting company in 2004, Dozier held the position of Vice President and General Manager, Operations at Boston Scientific's Miami operations centre, where he had responsibility for over 1,000 staff and a budget in excess of USD100 million per year.
David McIntyre
Chief Financial Officer, Company Secretary
David McIntyre joined HeartWare shortly after the IPO and he is an experienced medical device industry executive with both development-stage and large corporate credentials.
Prior to his appointment to HeartWare, Mr McIntyre was the Chief Financial Officer and General Counsel to another ASX-listed medical device company. He has previously served as a corporate and commercial law specialist in major international law firms, advising some of the world's largest corporations in various areas including mergers and acquisitions, corporate fundraising and securities law. He has also held senior financial roles in multinational companies, among them Rio Tinto.
David McIntyre holds a Bachelor of Economics, majoring in accounting from the University of Sydney and a Bachelor of Laws from the University of Technology, Sydney. He is admitted as a Solicitor of the Supreme Court of New South Wales and is a member of the Law Society of New South Wales and CPA Australia.
Jeffrey A. LaRose
Chief Scientific Officer
Jeff LaRose has been closely involved in the development of HeartWare's technology for seven years. He is responsible for all aspects of the design and physiological controls for HeartWare's HVAD. Jeff also leads the development of HeartWare's miniaturisation technology. He has held various positions related to technology, product development and intellectual property.
Jeff LaRose has 20 years experience in hydraulic technology development including roles with AEA Technology Engineering Software and Babcock and Wilcox. Mr LaRose holds a Master of Science in Mechanical Engineering.
Dr David R. Hathaway
Chief Medical Officer
Dr. Hathaway has previously served as Chief Medical Officer for several drug discovery and medical device companies. He has overseen the preclinical and clinical development of multiple products in the cardiology arena and has led the strategic development, outlicensing and commercial launch of a number of pharmaceuticals and medical technologies. He has extensive regulatory experience, having served on two successful NDA teams. Moreover, he has led successful partnering programs for Bristol-Myers Squibb, Knoll, Restoragen and Arginox Pharmaceuticals.
Dr Hathaway was previously Vice President of Medical Affairs with Knoll Pharmaceutical Company until it was acquired by Abbott Laboratories. While at Knoll he oversaw the Medical Affairs Department and was responsible for clinical research, regulatory affairs, medical information and drug advocacy. Prior to joining Knoll, Dr. Hathaway was Vice President, Cardiovascular Drug Discovery at Bristol-Myers Squibb, where he managed a team of 90 scientists in the preclinical development of novel antiarrhythmic and antithrombotic agents as well as new drugs for heart failure.
Before transitioning to a corporate career, Dr. Hathaway was Division Chief and Director of the Krannert Institute of Cardiology at the Indiana University School of Medicine, where he practiced for more than 14 years. He also served as a Clinical Associate and Cardiology Fellow at the National Institutes of Health in Bethesda, Md. While still a practicing clinician he invented a vascular closure technology which is currently marketed by Abbott Vascular as the Closer device and Prostar® Suture-Mediated Closure.
Dr. Hathaway has been section editor (Cardiovascular Diseases) of Kelley's Textbook of Medicine and was a member of the editorial boards of the Journal of Clinical Investigation, the Journal of the American College of Cardiology and Circulation. He has authored over 80 scientific and medical publications and is an inventor on 13 U.S. patents and 8 pending U.S. patent applications. He is a member of the Association of American Physicians, the American College of Physicians and the American Society for Clinical Investigation and is a fellow in the American College of Cardiology. He earned his medical degree from the Indiana University School of Medicine.
Howard Leibman
Head of Corporate Development
Howard brings to HeartWare a breadth of engineering and financial market experience. Prior to joining HeartWare, he was Associate Director, Corporate Finance at Emerging Growth Capital, a specialist investment bank with a focus on the biotechnology and medical device sectors. He advised on a number of successful initial public offerings, private capital raisings and other corporate transactions.
Howard's previous roles include Executive Director at Aeris Technologies, a company listed on the ASX, and Design Engineer at General Electric Company. He holds a Bachelor of Engineering (Electrical) and a Bachelor of Arts from the University of New South Wales and an MBA from the Australian Graduate School of Management and London Business School.
James Schuermann
Vice President, Sales and Marketing
Jim joined HeartWare in October 2007. He has overall responsibility for HeartWare's sales and marketing activities across all markets.
Jim has over 15 years sales and marketing experience in the medical device arena. Prior to joining HeartWare, he spent nine years in sales and marketing at Boston Scientific Corporation. Over this time he progressed from sales through product management until being appointed Director of Marketing in 2005. With 5 direct reports and a broader team of over 150 product managers and salespeople, Jim led the marketing activities for a US$280M worldwide business which emerged as one of the strongest in the company. Before joining Boston Scientific, he spent 5 years in medical sales and sales management at Sherwood Davis & Geck. Jim received his undergraduate degree in marketing from Kelley School of Business, Indiana University, Bloomington, and his MBA from Ageno School of Business, Golden Gate University, San Francisco.
Jennifer Foley
Vice President, Clinical and Regulatory Affairs (effective from 22 November 2006)
Jennifer has extensive experience in clinical and regulatory activities. She currently holds the position of Vice-President, Clinical Sciences, Clinical Program Management and Operations at Boston Scientific Corporation. As one of the most senior executives within Boston Scientific's clinical affairs organization, she is responsible for overseeing the execution of clinical trials across 9 of the company's divisions. In aggregate, these divisions generate sales of approximately US$6 billion per year.
Prior to joining Boston Scientific in 2002, Jennifer was responsible for managing major trials with The Medicines Company (NASDAQ:MDCO) and Glaxo (now GlaxoSmithKline, NYSE:GSK). She previously spent 5 years in leadership positions at Parexel International Corporation (NASDAQ:PRXL), one of the world's largest contract research organizations.
Medical Advisory Board
Bud Frazier, M.D.
(Texas Heart Institute)
- Chairman of Advisory Board
- Chief of Transplant Services, Texas Heart Institute
- Implanted over 565 LVADs
Steven Boyce, M.D.
(Washington Hospital Centre)
- Director of Heart Transplantation, Washington Hospital Centre
- Involved with the development of HeartWare devices since 1996
Leslie Miller, M.D.
(Lillehei Heart Institute University of Minnesota)
- Director of Heart Failure/Heart Transplant Program at the University of Minnesota
- Past President of the International Society for Heart and Lung Transplantation
Laman A. Gray, Jr., M.D.
(University of Louisville School of Medicine)
- Professor of Surgery and Director of Thoracic and Cardiovascular Surgery at the University of Louisville School of Medicine
- Was the original investigator for the Novacor VAD System, and implanted the first AbioCor Implantable Replacement Heart
Stephen Westaby M.D., Ph.D
(John Radcliffe Hospital, Oxford)
- Cardiothoracic surgeon, John Radcliffe Hospital
- Over 500 cardiac operations annually
- Implanted the longest surviving LVAD patient, Peter Houghton
Georg Wieselthaler, M.D.
(Vienna General Hospital)
- Clinical Director of Mechanical Circulatory Support, Vienna General Hospital
- Secretary General of the International Society of Rotary Blood Pumps
Gerrie O'Driscoll, M.D.
(Royal Perth Hospital)
- Consultant Cardiologist, Royal Perth Hospital
- Medical Head, West Australian Advanced Heart Failure and Cardiac Transplant Service
- Extensive experience with a range of LVAD devices
updated 30th April, 2008
| © Copyright 1996-2008 irasia.com Ltd. All rights reserved. Tel: (852) 2831-9792. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |